NasdaqCM:VKTXBiotechs
Viking Therapeutics Buyout Buzz Meets VK2735 Obesity Drug Valuation Gap
Viking Therapeutics is drawing fresh attention as a potential acquisition target, centered on its obesity drug candidate VK2735.
Both injectable and oral forms of VK2735 are in late stage development, making the company a focus for larger pharmaceutical buyers.
Market speculation has recently pointed to major firms such as Eli Lilly and Pfizer as possible suitors.
For investors tracking NasdaqCM:VKTX, this buyout chatter sits against a mixed share price backdrop. The stock closed at $30.8,...